Cannabis

Product

Last mentioned: Mar 10, 2026

Stories mentioning Cannabis 2

pharma Bullish

Cannabis Compounds Show Potential to Reverse MASLD in One-Third of Adults

Emerging research indicates that specific non-psychoactive cannabis compounds, particularly THCV, may reverse Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). This breakthrough offers a potential pharmaceutical path for a condition that currently affects nearly 33% of the global adult population.

2 sources
market-trends Bullish

Cannabis Compounds Show Potential to Reverse MASLD in One-Third of Adults

Emerging clinical research indicates that specific cannabis-derived compounds may reverse Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), a condition affecting nearly 33% of the global adult population. This discovery could shift the treatment paradigm for a disease that currently has few FDA-approved pharmacological interventions.

2 sources